Form 4: Immunocore Holdings Executive Sells Shares Under 10b5-1 Trading Plan

David M. Berman, Head of R&D at Immunocore Holdings plc, executed transactions involving ordinary shares, including exercising options and selling shares, under a pre-arranged 10b5-1 trading plan.

Summary

• David M. Berman, Head of R&D at Immunocore Holdings plc, reported transactions involving the company's ordinary shares on February 28, 2024.
• These transactions included the exercise of employee share options to acquire 36,509 ordinary shares at a price of $17.46 per share.
• Simultaneously, Berman sold 16,900 shares at a weighted average price of $67.61, 7,472 shares at $68.84, 10,937 shares at $69.73 and 1,200 shares at $70.45.
• The sales were executed under a Rule 10b5-1 trading plan adopted on March 6, 2023.
• Following these transactions, Berman holds 0 ordinary shares directly and 271,790 employee share options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports transactions under a pre-existing plan. There's no inherent positive or negative signal, but the sale of shares could be perceived slightly negatively by some investors.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of shares by a company executive could be perceived negatively by some investors, although it's part of a pre-planned strategy.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, particularly in the biotechnology sector. These transactions are often scrutinized by investors for insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a standard tool used by executives to sell shares while avoiding accusations of insider trading.
• The size and frequency of executive stock sales can vary widely depending on the company's size, stage of development, and compensation policies.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates